ReviewTheranostics2021
COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges.
Review in Theranostics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 127 citations in OpenAlex.
- Pooled it
- Efficacy and safety of 7-day aerosolized epigallocatechin-3-gallate in oncologic patients with COVID-19 pneumonia.BMC cancer · 2026Trial
- Cytokine and Lymphocyte Profiles in COVID-19 Patients with Cancer: Implications for Disease Severity and Clinical Outcomes.Viruses · 2026Article
- Weathering the Double Storm-Resilience in Chinese Older Cancer Patients With Long COVID: A Qualitative Study.Journal of advanced nursing · 2026Article
- Status and trends of early-onset cancers and their risk factors in China: population-based study.Journal of global health · 2026Article
- COVID-19 infection and cancer regression: a review of current evidence, potential mechanisms, and clinical perspectives on a Paradoxical phenomenon.Infectious agents and cancer · 2025Review
- Bridging Cancer and COVID-19: The Complex Interplay of ACE2 and TMPRSS2.Cancer medicine · 2025Review
- Impact of the COVID-19 Pandemic on the Treatment of Head and Neck Cancers.Journal of clinical medicine · 2025Article
- Predicting the hub interactome of COVID-19 and oral squamous cell carcinoma: uncovering ALDH-mediated Wnt/β-catenin pathway activation via salivary inflammatory proteins.Scientific reports · 2025Article
- Bidirectional approach of Punica granatum natural compounds: reduction in lung cancer and SARS-CoV-2 propagation.BMC complementary medicine and therapies · 2025Article
- Bruton's Tyrosine Kinase Inhibitors: A Versatile Therapeutic Approach for Cancer, Autoimmune Disorders, GVHD and COVID-19.Mini reviews in medicinal chemistry · 2025Review
- Altered ACE2 and interferon landscape in the COVID-19 microenvironment correlate with the anti-PD-1 response in solid tumors.Cellular and molecular life sciences : CMLS · 2024Article
- The signature of SARS-CoV-2-related genes predicts the immune therapeutic response and prognosis in breast cancer.BMC medical genomics · 2024Article
- Risk of COVID-19 infection in patients with NSCLC receiving EGFR-TKI targeted therapy during the first wave in China.The Journal of international medical research · 2024Article
- Radiotracers for Molecular Imaging of Angiotensin-Converting Enzyme 2.International journal of molecular sciences · 2024Review
- Trends analysis of cancer incidence, mortality, and survival for the elderly in the United States, 1975-2020.Cancer medicine · 2024Article
- Successful treatment and remission of advanced testicular cancer after COVID-19 infection during induction chemotherapy.IJU case reports · 2024Article
- Challenges in Treating Pediatric Cancer Patients during the COVID-19 Pandemic: Balancing Risks and Care.Viruses · 2024Review
- Comprehensive analysis of the potential pathogenesis of COVID-19 infection and liver cancer.World journal of gastrointestinal oncology · 2024Article
- Bioinformatics and system biology approach to identify the influences among COVID-19, influenza, and HIV on the regulation of gene expression.Frontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
Abstract
The coronavirus disease 2019 (COVID-19) is a viral disease caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that affects the respiratory system of infected individuals. COVID-19 spreads between humans through respiratory droplets produced when an infected person coughs or sneezes. The COVID-19 outbreak originated in Wuhan, China at the end of 2019. As of 29 Sept 2020, over 235 countries, areas or territories across the globe reported a total of 33,441,919 confirmed cases, and 1,003,497 confirmed deaths due to COVID-19. Individuals of all ages are at risk for infection, but in most cases disease severity is associated with age and pre-existing diseases that compromise immunity, like cancer. Numerous reports suggest that people with cancer can be at higher risk of severe illness and related deaths from COVID-19. Therefore, managing cancer care under this pandemic is challenging and requires a collaborative multidisciplinary approach for optimal care of cancer patients in hospital settings. In this comprehensive review, we discuss the impact of the COVID-19 pandemic on cancer patients, their care, and treatment. Further, this review covers the SARS-CoV-2 pandemic, genome characterization, COVID-19 pathophysiology, and associated signaling pathways in cancer, and the choice of anticancer agents as repurposed drugs for treating COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.